Immunomodulatory treatment strategies in multiple sclerosis

Bernd C. Kieseier, Heinz Wiendl, Verena I. Leussink, Olaf Stüve

Research output: Contribution to journalArticle

24 Scopus citations


Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults. The mainstays in the immunomodulatory therapy of MS are currently interferon beta and glatiramer acetate, both of which have proven to be clinically and paraclinically effective. Current clinical evidence indicates that treatment should be initiated as early as possible. In this review we summarize available data from clinical studies on clinical efficacy of immunomodulatory drugs for treating patients with multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)15-21
Number of pages7
JournalJournal of Neurology
Issue numberSUPPL. 6
Publication statusPublished - Dec 2008



  • Glatiramer acetat
  • Immunomodulation
  • Interferon beta
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this